Welcome to our dedicated page for Bausch + Lomb news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb stock.
Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Summary not available.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced 25 presentations during the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from May 5-8, 2023. This includes 21 podium presentations and four poster presentations, with highlights on the new StableVisc™ device and the LOTEMAX® ophthalmic gel. Bausch + Lomb will also sponsor two educational events focusing on dry eye disease and the IC-8 Apthera lens. Approximately 18 million Americans are affected by dry eye disease, emphasizing the significance of the topics discussed. Notably, new data from the ARMOR study will be presented, aiming to address antibiotic resistance in ocular microorganisms.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) held its 2023 annual meeting on April 24, 2023, where shareholders elected 10 directors. Key voting results included:
- Nathalie Bernier: 344,100,848 votes for, 124,733 against
- Richard U. De Schutter: 344,094,979 votes for, 130,602 against
- Gary Hu: 344,016,782 votes for, 208,799 against
- Brett Icahn: 344,072,707 votes for, 152,874 against
In addition to the elections, shareholders approved the advisory compensation of executives, an amendment to increase shares under the 2022 Omnibus Incentive Plan, and appointed PricewaterhouseCoopers LLP as the independent accounting firm until the 2024 annual meeting. The results will be filed with the SEC.
Bausch + Lomb Corporation has launched two new ophthalmic viscosurgical devices (OVDs), StableVisc and TotalVisc, aimed at enhancing cataract surgery outcomes. These devices provide dual-action protection, addressing concerns about free radical damage during surgical procedures. StableVisc maintains anterior chamber space, while TotalVisc combines both StableVisc and ClearVisc for comprehensive ocular protection.
With a fill volume of one milliliter, StableVisc leads its segment, reducing the need for multiple packs during surgery. The devices contain sodium hyaluronate and sorbitol, offering a strong barrier against free radicals, which can lead to post-surgical complications.
This launch positions Bausch + Lomb as a leader in innovative solutions for eye health, particularly in the competitive cataract surgery market.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced eight scientific poster presentations at the ARVO annual meeting in New Orleans from April 23-27, 2023. Highlights include results from the 12-month KALAHARI safety extension study of NOV03 (perfluorohexyloctane) and data on XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use. Notable studies presented include antibiotic resistance patterns from the ARMOR surveillance study and evaluations on intraocular lens pipeline programs. Bausch + Lomb remains committed to advancing research and innovation in eye health to meet patient needs.
Bausch + Lomb Corporation (BLCO) has announced significant achievements in its eye care recycling initiatives. The ONE by ONE and Biotrue® Eye Care Recycling programs have successfully recycled a total of 65.8 million units, equivalent to 397,194 pounds of waste, since their inception. The ONE by ONE program, launched in 2016, has collected over 65 million used contact lenses and related materials, while the Biotrue® program, initiated in 2021, has gathered more than 440,000 eye drop units and lens cases. With nearly 13,000 eye care practices participating, these programs aim to mitigate plastic waste and contribute to sustainability efforts. Bausch + Lomb collaborates with TerraCycle for recycling operations, emphasizing their commitment to environmental health.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) will release its first-quarter 2023 financial results on May 3, 2023, at 8:00 a.m. ET. The company will conduct a conference call and live webcast to discuss these results and provide a business update. Interested parties can access the webcast through the Investor Relations section of the Bausch + Lomb website. Additionally, a replay of the conference call will be available until May 17, 2023.
Bausch + Lomb operates globally with over 400 products in its portfolio, emphasizing eye health. Founded in 1853, the company employs approximately 13,000 individuals and maintains a presence in nearly 100 countries.
Bausch + Lomb and Heidelberg Engineering have launched the SeeLuma™ Fully Digital Surgical Visualization Platform, enhancing surgical procedures for ophthalmic surgeons. The platform provides superior visualization compared to existing surgical microscopes, featuring heads-up 3D monitors, multiple digital display options, and an intuitive interface. First launched in the United States and Western Europe, SeeLuma aims to improve surgical outcomes through its ergonomic design and educational features. The high-quality imaging capabilities, including 4K resolution and enhanced anatomical landmark visualization, position SeeLuma as a key tool for modern ophthalmic surgeries. This innovation reflects the companies' commitment to advancing surgical technology and improving patient care.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced on April 12, 2023, the appointments of Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President of Ophthalmic Pharmaceuticals, effective April 24, 2023. Both will join the executive management team. Christina Ackermann will step down from her role and leave the company on April 28, 2023. Brent Saunders, the company's CEO, expressed confidence in Bailey and Stewart's ability to create value and ensure long-term success for Bausch + Lomb. Bailey returns after 18 years, while Stewart comes with extensive experience from AbbVie, focusing on enhancing the company’s prescription medicines and ophthalmic product portfolio.
Bausch + Lomb Corporation (BLCO) and Novaliq GmbH announced the publication of Phase 3 trial results for NOV03 (perfluorohexyloctane), a potential treatment for dry eye disease linked to Meibomian gland dysfunction. The trial met primary efficacy endpoints, demonstrating significant improvements in both corneal staining and dryness scores at 8 weeks. NOV03, which targets excessive tear evaporation, was well tolerated with minor adverse events. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2023, with further data expected from ongoing studies, marking an important step for addressing the needs of millions suffering from this condition.